MustGrow Biologics sees massive growth in patent portfolio

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

MustGrow Biologics CEO Corey Giasson joined Steve Darling from Proactive to share news the company has seen its portfolio of patents grow exponentially.

Giasson tells Proactive its IP portfolio has grown from 23 to 84 total patents issued and pending over the last three years. In fact, 62 have been issued which is an increase from 18 issued patents three years ago.

Contact Details

Proactive Canada

+1 604-688-8158

na-editorial@proactiveinvestors.com

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  248.23
+0.00 (0.00%)
AAPL  330.32
+0.00 (0.00%)
AMD  615.73
+0.00 (0.00%)
BAC  53.73
+0.00 (0.00%)
GOOG  334.93
+0.00 (0.00%)
META  725.93
+0.00 (0.00%)
MSFT  512.80
+0.00 (0.00%)
NVDA  230.86
+0.00 (0.00%)
ORCL  138.07
+0.00 (0.00%)
TSLA  354.11
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.